<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9542">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05695781</url>
  </required_header>
  <id_info>
    <org_study_id>BRM421-22-C001-PR</org_study_id>
    <nct_id>NCT05695781</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Subjects With Dry Eye.</brief_title>
  <official_title>A Multi-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAEÂ®) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BRIM Biotechnology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BRIM Biotechnology Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for&#xD;
      the treatment of the signs and symptoms of dry eye disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Masking</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Sign: Change From Baseline in Total Corneal Fluorescein Staining Score</measure>
    <time_frame>1-2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Symptom: Change From Baseline in Visual Analog Scale (VAS)</measure>
    <time_frame>1-2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">732</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>BRM421 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRM421 Ophthalmic Solution</intervention_name>
    <description>A topical drop of BRM421 ophthalmic solution.</description>
    <arm_group_label>BRM421 Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>A topical drop of vehicle (minus active) ophthalmic solution.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age;&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Have a reported history of dry eye prior to enrollment;&#xD;
&#xD;
          -  Have a history of use or desire to use eye drops;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any clinically significant slit lamp findings at Visit 1 that may include active&#xD;
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active&#xD;
             ocular allergies that require therapeutic treatment, and/or in the opinion of the&#xD;
             investigator may interfere with study parameters;&#xD;
&#xD;
          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active&#xD;
             ocular inflammation at Visit 1;&#xD;
&#xD;
          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses&#xD;
             during the study;&#xD;
&#xD;
          -  Have used any eye drops within 2 hours of Visit 1;&#xD;
&#xD;
          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the&#xD;
             last 12 months;&#xD;
&#xD;
          -  Be a woman of childbearing potential who is not using an acceptable means of birth&#xD;
             control;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 13, 2023</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

